Pulmonx Corp. (LUNG): Price and Financial Metrics

Pulmonx Corp. (LUNG): $9.27

0.16 (+1.76%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

LUNG Price/Volume Stats

Current price $9.27 52-week high $14.84
Prev. close $9.11 52-week low $7.75
Day low $9.12 Volume 943,200
Day high $9.46 Avg. volume 495,303
50-day MA $11.55 Dividend yield N/A
200-day MA $11.35 Market Cap 357.24M

LUNG Stock Price Chart Interactive Chart >

LUNG POWR Grades

  • Sentiment is the dimension where LUNG ranks best; there it ranks ahead of 68.91% of US stocks.
  • The strongest trend for LUNG is in Sentiment, which has been heading up over the past 26 weeks.
  • LUNG ranks lowest in Momentum; there it ranks in the 4th percentile.

LUNG Stock Summary

  • PULMONX CORP's stock had its IPO on October 1, 2020, making it an older stock than just 12.91% of US equities in our set.
  • With a price/sales ratio of 7.1, PULMONX CORP has a higher such ratio than 85.12% of stocks in our set.
  • With a year-over-year growth in debt of 67.72%, PULMONX CORP's debt growth rate surpasses 89.05% of about US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to PULMONX CORP are DMTK, TNON, EKSO, ASPN, and SGHT.
  • LUNG's SEC filings can be seen here. And to visit PULMONX CORP's official web site, go to pulmonx.com.

LUNG Valuation Summary

  • LUNG's EV/EBIT ratio is -7.5; this is 151.37% lower than that of the median Healthcare stock.
  • LUNG's price/sales ratio has moved down 33.4 over the prior 39 months.

Below are key valuation metrics over time for LUNG.

Stock Date P/S P/B P/E EV/EBIT
LUNG 2023-12-29 7.5 3.9 -8.0 -7.5
LUNG 2023-12-28 7.7 4.0 -8.2 -7.7
LUNG 2023-12-27 7.7 4.0 -8.2 -7.7
LUNG 2023-12-26 7.7 3.9 -8.1 -7.6
LUNG 2023-12-22 7.5 3.9 -7.9 -7.5
LUNG 2023-12-21 7.5 3.9 -7.9 -7.5

LUNG's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • LUNG has a Quality Grade of D, ranking ahead of 6.24% of graded US stocks.
  • LUNG's asset turnover comes in at 0.2 -- ranking 142nd of 186 Medical Equipment stocks.
  • 500 - Internal server error

The table below shows LUNG's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.200 0.720 -0.626
2020-12-31 0.206 0.648 -0.660

LUNG Price Target

For more insight on analysts targets of LUNG, see our LUNG price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $55.67 Average Broker Recommendation 1.5 (Moderate Buy)

Pulmonx Corp. (LUNG) Company Bio


Pulmonx Corp. provides interventional pulmonology, planning tools, and treatments for obstructive lung diseases. It carries out its operations in the following geographical locations: Europe, Middle East and Africa (EMEA), Asia Pacific, Other International, and United States. It offers the Zephyr Endobronchial Valve, an implantable device used to occlude all airways feeding the hyperinflated lobe of a lung that is most diseased with emphysema. It also offers StratX Lung Analysis, a platform designed to treat severe emphysema, and the Chartis Assessment System, a pulmonary assessment system. The company was founded by Rodney C. Perkins and is headquartered in Redwood City, CA.


LUNG Latest News Stream


Event/Time News Detail
Loading, please wait...

LUNG Latest Social Stream


Loading social stream, please wait...

View Full LUNG Social Stream

Latest LUNG News From Around the Web

Below are the latest news stories about PULMONX CORP that investors may wish to consider to help them evaluate LUNG as an investment opportunity.

Insider Sell: President and CEO French Glendon E. III Sells 10,000 Shares of Pulmonx Corp (LUNG)

Pulmonx Corp (NASDAQ:LUNG), a company specializing in medical devices for the treatment of pulmonary disorders, has reported an insider sell according to a recent SEC filing.

Yahoo | December 23, 2023

The Honest Company Announces Appointment of Michael Barkley, Alissa Hsu Lynch, and Andrea Turner to the Board of Directors

LOS ANGELES, Dec. 11, 2023 (GLOBE NEWSWIRE) -- The Honest Company (NASDAQ: HNST), a digitally-native consumer products company dedicated to creating clean- and sustainably-designed products spanning baby care, beauty, personal care, wellness and household care, today announced that Michael Barkley, Former Chief Executive Officer of Kind LLC, Alissa Hsu Lynch, Former Global Head of MedTech Strategy and Solutions for Google Cloud, and Andrea Turner, Former Senior Vice President, Global Customer Se

Yahoo | December 11, 2023

Biotech Breakthroughs: 3 Revolutionary Stocks Redefining Healthcare

The article embarks on a transformative journey through the biopharmaceutical frontier, where the listed companies stand as titans reshaping healthcare norms.

Yiannis Zourmpanos on InvestorPlace | November 17, 2023

Pulmonx to Present at the Piper Sandler 35th Annual Healthcare Conference

REDWOOD CITY, Calif., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference in New York on Wednesday, November 29, 2023, at 11:00 AM PT / 2:00 PM ET. A live and archived webcast of the presentation will be available on “Investors” section of the Pulmonx website at https://in

Yahoo | November 15, 2023

Pulmonx to Participate at Upcoming Investor Conferences

REDWOOD CITY, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in two upcoming investor conferences. Pulmonx management is scheduled to participate in a fireside chat at the Stifel 2023 Healthcare Conference in New York on Tuesday, November 14, 2023, at 11:25am PT / 2:25pm ET. Interested parties may access a live and archived webcast

Yahoo | October 31, 2023

Read More 'LUNG' Stories Here

LUNG Price Returns

1-mo -0.96%
3-mo -27.29%
6-mo -10.26%
1-year -15.50%
3-year -78.93%
5-year N/A
YTD -27.29%
2023 51.25%
2022 -73.71%
2021 -53.54%
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!